Aimei Health Technology Co., Ltd. Files Definitive Proxy Statement

TL;DR

Aimei Health (AH) filed its proxy statement. EGM coming up. No fee paid.

AI Summary

Aimei Health Technology Co., Ltd. filed a Definitive Proxy Statement (DEF 14A) on December 3, 2024, for its fiscal year ending December 31. The company, located at 10 East 53rd Street, Suite 3001, New York, NY 10022, is holding an Extraordinary General Meeting of Shareholders. The filing indicates no fee was required for this submission.

Why It Matters

This filing provides shareholders with crucial information regarding upcoming meetings and company decisions, allowing them to exercise their voting rights effectively.

Risk Assessment

Risk Level: low — This is a routine filing of a proxy statement, which is standard for public companies and does not inherently indicate new risks.

Key Numbers

• 0001493152-24-048354 — Accession Number (Unique identifier for the SEC filing)
• 001-41880 — SEC File Number (Company's SEC registration number)

Key Players & Entities

• Aimei Health Technology Co., Ltd. (company) — Registrant
• 10 East 53rd Street, Suite 3001, New York, NY 10022 (address) — Company Business and Mail Address
• December 3, 2024 (date) — Filing Date
• December 2, 2024 (date) — Period of Report
• December 31 (date) — Fiscal Year End

FAQ

Key Financial Figures

• $0.033 — its initial business combination, from $0.033 per Public Share (as defined below) (fo
• $50,000 — to an amount equal to the lesser of (i) $50,000 for all outstanding Public Shares and (
• $10.57 — o;Record Date”) was approximately $10.57 per public share. The closing price of
• $10.58 — h’s shares on the Record Date was $10.58. Aimei Health cannot assure shareholder
• $25,000 — Ltd for an aggregate purchase price of $25,000 (the “Founder Shares”) or t

Filing Documents

• formdef14a.htm (DEF 14A) — 292KB
• proxy_001.jpg (GRAPHIC) — 390KB
• proxy_002.jpg (GRAPHIC) — 397KB
• 0001493152-24-048354.txt ( ) — 1378KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant   Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Section 240.14a-12 AIMEI HEALTH TECHNOLOGY CO., LTD (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. AIMEI HEALTH TECHNOLOGY CO., LTD 10 East 53rd Street, Suite 3001 New York, NY 10022 +34 678 035200 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 23, 2024 TO THE SHAREHOLDERS OF AIMEI HEALTH TECHNOLOGY CO., LTD: You are cordially invited to attend the extraordinary general meeting of shareholders of Aimei Health Technology Co., Ltd (“Aimei Health,” “Company,” “we,” “us” or “our”) to be held on December 23, 2024 in person in the offices of the Company’s counsel, Hunter Taubman Fischer & Li LLC, at 950 Third Avenue, 19th Floor, New York, NY 10022 and virtually at 11:00 a.m. Eastern Time (the “Extraordinary General Meeting”), or at such other time, on such other date and at such other place at which the meeting may be adjourned. If you plan on attending the Extraordinary General Meeting in person please email xiejunheng@aimeihealth.com at least one day prior to the Extraordinary General Meeting. If you plan on attending the Extraordinary General Meeting online, you will be able to vote and submit your questions during the Extraordinary General Meeting by visiting https://www.virtualshareholdermeeting.com/AFJKU2024 shortly prior to the start of the meeting and entering the 16-digit control number found on the proxy card or voting instruction form. A person participating in the Extraordinary General Meeting in the virtual meeting format is deemed to be present in person at the meeting. The purpose of the Extraordinary General Meeting will be to consider and vote on the following proposals: 1. Proposal 1 – To approve an amendment to the Investment Management Trust Agreement dated December 1, 2023 (the “Trust Agreement”), entered into by and between Continental Stock Transfer & Trust Company, as trustee (the “Trustee”) and the Company governing the trust account established in connection with the Company’s initial public offering (“IPO”), to amend the amount of funds to be deposited by our sponsor, Aimei Investment Ltd (the “Sponsor”) into the Trust Account (as defined below) in connection with extending the timeframe within which the Company must consummate its initial business combination, from $0.033 per Public Share (as defined below) (for each monthly extension) to an amount equal to the lesser of (i) $50,000 for all outstanding Public Shares and (ii) $0.033 for each outstanding Public Share (for each monthly extension) (the “Trust Agreement Amendment Proposal” or “Proposal 1”); and 2. Proposal 2 – To approve, by ordinary resolution, to direct the chairman of the Extraordinary General Meeting to adjourn the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes for, or otherwise in connection with, the approval of Proposal 1(the “Adjournment Proposal” or “Proposal 2”). Each of the Trust Agreement Amendment Proposal and the Adjournment Proposal (together the “Proposals”) is more fully described in the accompanying proxy statement. Please take the time to read carefully each of the Proposals in the accompanying proxy statement before you vote. The Amended and Restated Articles of Association of the Company (the “Articles”) and the Trust Agreement provide that the Company has until 12 months from the closing of its IPO (“Combination Period”) to consummate its initial business combination (namely, until December 6, 2024). The Articles and the Trust Agreement also provide that if the board of directors (the “Board”) anticipates that we may not be able to consummate our initial business combination within the Combination Period, we may, by resolution of the Board if requested by our Sponsor, extend the Combination Period up to twelve (12) times each for an additional one month (each, a “Monthly Extension”) from December 6, 2024 (i.e., 12 months

View Full Filing

View this DEF 14A filing on SEC EDGAR